Dr. Rakesh Parekh was in his mid-40s when he first noticed something was wrong: During his workouts, his left arm was weaker and struggled to keep up. Initially, Parekh, an emergency medicine doctor ...

Researchers think they know why GLP-1 drugs appear to reduce alcohol cravings GLP-1 drugs slow the speed at which alcohol enters the bloodstream This diminishes its effects on a person’s brain ...

Drug maker Novo Nordisk says semaglutide, the active ingredient for the weight loss jab Wegovy, does not slow Alzheimer's - despite initial hopes that it might help against dementia. Researchers began ...

Donanemab slowed cognitive decline by about 35% in a phase 3 clinical trial, according to a report released Monday. Another drug is showing promise for those at risk of Alzheimer's disease. Donanemab, ...

Apart from their widely celebrated effect at weight loss and diabetes management, GLP-1 drugs like Ozempic and Wegovy might also reduce alcohol use. In a pilot study published in Scientific Reports, ...

With over 7 million people over 65 dealing with the degenerative disease — and the number expected to almost double by 2050 — Alzheimer’s is the most common form of dementia. But two new ...

A new drug may slow progression of — and even reverse — symptoms of a rare form of amyotrophic lateral sclerosis, or ALS, a new study published Monday finds. The drug, tofersen, targets a very ...

Deciding which jab to nab? When it comes to shedding pounds and cinching inches, a new study puts one weight loss drug ahead of another. Published in the New England Journal of Medicine, the study ...

When Jean Kay started a brand-new multiple sclerosis treatment called Rebif in 2003, it cost $17,500 a year. That was pricey, but her insurance covered most of it, and the drug slowed the disease’s ...